Document is current
Any future updates will be listed below
-
Authors
Starr, Lynn
Dutta, Sanjoy https://orcid.org/0000-0001-8117-1677
Danne, Thomas https://orcid.org/0000-0002-8424-3944
Karpen, Stephen R. https://orcid.org/0000-0002-9063-8010
Hutton, Campbell https://orcid.org/0000-0002-3897-3882
Kowalski, Aaron https://orcid.org/0000-0002-0979-5343
- License Information
-
More Information
Article History
Received: 12 February 2025
Accepted: 24 March 2025
First Online: 11 April 2025
Declarations
:
: Lynn Starr, Sanjoy Dutta, Thomas Danne, Campbell Hutton, Stephen Karpen, and Aaron Kowalski are employed by Breakthrough T1D. Thomas Danne has received speaker fees and research support from or has consulted for Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Novo Nordisk, Provention Bio, Roche, Sanofi and Vertex Pharmaceuticals; and is a shareholder of DreaMed Ltd.
: The information presented in this article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
